Anaplastic thyroid cancers (ATC) are aggressive tumors, which exhibit cell cycle misregulations leading to uncontrolled cellular proliferation and genomic instability. They fail to respond to chemotherapeutic agents and radiation therapy and most patients die within few months from the diagnosis. In the present study, we evaluated the in vitro effects on ATC cells of VX-680, an inhibitor of the Aurora serine/threonine kinases involved in the regulation of multiple aspects of chromosome segregation and cytokinesis. The effects of VX-680 on proliferation, apoptosis, soft agar colony formation, cell cycle and ploidy were tested on the ATC derived cell lines CAL-62, 8305C, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibited proliferation in a time- and dose-dependent manner, with the IC50 comprised between 25 nM and 150 nM. The VX-680 significantly impaired the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity showed that VX-680 induced apoptosis in the different cell lines. CAL-62 cells exposed 12 h to VX-680 showed an accumulation of cells with ≥ 4N DNA content. Time-lapse analysis demonstrated that VX-680 treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation was abrogated following VX-680 treatment. In conclusion, our data demonstrated that VX-680 is effective in reducing cell growth of different ATC derived cell lines and warrant further investigation to exploit its potential therapeutic value for ATC treatment.

Effects of the Aurora kinases inhibitor VX-680 on anaplastic thyroid cancer derived cell lines / Arlot Bonnemains, Y; Baldini, Enke; Veltri, A; Di Fiore, A; Dainelli, M; Curcio, F; Ambesi Impiombato, Fs; Ulisse, Salvatore; D'Armiento, Massimino. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. SUPPLEMENT. - ISSN 1121-1369. - STAMPA. - 31 (Suppl.to No. 4):(2008), pp. 8-8. (Intervento presentato al convegno XXVII Giornate Endocrinologiche Pisane tenutosi a Pisa nel 26-28 giugno, 2008).

Effects of the Aurora kinases inhibitor VX-680 on anaplastic thyroid cancer derived cell lines

BALDINI, ENKE;ULISSE, SALVATORE;D'ARMIENTO, Massimino
2008

Abstract

Anaplastic thyroid cancers (ATC) are aggressive tumors, which exhibit cell cycle misregulations leading to uncontrolled cellular proliferation and genomic instability. They fail to respond to chemotherapeutic agents and radiation therapy and most patients die within few months from the diagnosis. In the present study, we evaluated the in vitro effects on ATC cells of VX-680, an inhibitor of the Aurora serine/threonine kinases involved in the regulation of multiple aspects of chromosome segregation and cytokinesis. The effects of VX-680 on proliferation, apoptosis, soft agar colony formation, cell cycle and ploidy were tested on the ATC derived cell lines CAL-62, 8305C, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibited proliferation in a time- and dose-dependent manner, with the IC50 comprised between 25 nM and 150 nM. The VX-680 significantly impaired the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity showed that VX-680 induced apoptosis in the different cell lines. CAL-62 cells exposed 12 h to VX-680 showed an accumulation of cells with ≥ 4N DNA content. Time-lapse analysis demonstrated that VX-680 treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation was abrogated following VX-680 treatment. In conclusion, our data demonstrated that VX-680 is effective in reducing cell growth of different ATC derived cell lines and warrant further investigation to exploit its potential therapeutic value for ATC treatment.
2008
XXVII Giornate Endocrinologiche Pisane
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
Effects of the Aurora kinases inhibitor VX-680 on anaplastic thyroid cancer derived cell lines / Arlot Bonnemains, Y; Baldini, Enke; Veltri, A; Di Fiore, A; Dainelli, M; Curcio, F; Ambesi Impiombato, Fs; Ulisse, Salvatore; D'Armiento, Massimino. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. SUPPLEMENT. - ISSN 1121-1369. - STAMPA. - 31 (Suppl.to No. 4):(2008), pp. 8-8. (Intervento presentato al convegno XXVII Giornate Endocrinologiche Pisane tenutosi a Pisa nel 26-28 giugno, 2008).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/488370
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact